Personalized tumor response assessment in the era of molecular medicine: Cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST

American Journal of Roentgenology

Volumn 198, Issue 4, 2012, Pages 737-745

  Nishino, Mizuki ^a,b   Jagannathan, Jyothi P ^a,b   Krajewski, Katherine M ^a,b   O'Regan, Kevin ^a,b   Hatabu, Hiroto ^b   Shapiro, Geoffrey ^a   Ramaiya, Nikhil H ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CT; Personalized medicine; RECIST; Response assessment

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CRIZOTINIB; FLUORODEOXYGLUCOSE F 18; IMATINIB; IMMUNOMODULATING AGENT; IPILIMUMAB; PACLITAXEL; PLATINUM COMPLEX; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR INHIBITOR;

CANCER GROWTH; CANCER MORPHOLOGY; CANCER SIZE; CANCER SPECIFIC RESPONSE CRITERIA; CANCER SURVIVAL; CANCER THERAPY; CHESON CRITERIA; CHOI RESPONSE CRITERIA; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; DRUG MECHANISM; DRUG RESPONSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNE RELATED RESPONSE CRITERIA; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MASS ATTENUATION SIZE AND STRUCTURE CRITERIA; MELANOMA; METASTASIS; MOLECULAR THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; REVIEW; THERAPY SPECIFIC RESPONSE CRITERIA; TUMOR VOLUME; WORLD HEALTH ORGANIZATION CRITERIA;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELANOMA; MOLECULAR TARGETED THERAPY; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84859118421     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7483     Document Type: Review

References (57)

1. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480 (Pubitemid 34879334)
2. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26:626-632 (Pubitemid 351264358)
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139 (Pubitemid 38637993)
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500 (Pubitemid 38720929)
5. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311 (Pubitemid 39209661)
6. McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 2009; 27:5650-5659
7. Macconaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol 2010; 28:5219-5228
8. World Health Organization. WHO handbook for reporting results of cancer treatment: offset publication no. 48. Geneva, Switzerland: World Health Organization, 1979
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214 (Pubitemid 11167383)
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst 2000; 92:205-216 (Pubitemid 30099779)
11. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
12. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. RadioGraphics 2008; 28:329-344
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244-1253 (Pubitemid 29162950)
14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586 (Pubitemid 350002966)
15. Choi H, Charnsangavej C, Faria SC, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG-PET findings. AJR 2004; 183:1619-1628 (Pubitemid 44210530)
16. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759 (Pubitemid 46797957)
17. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235:892-898
18. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25:1760-1764 (Pubitemid 46797958)
19. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(suppl 5):v98-v102
20. Benjamin RS, Schöffski P, Hartmann JT, et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 2011; 68:69-77
21. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008; 13(suppl 2):4-7
22. Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: tumor response assessment - pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009;251:447-456
23. Faivre S, Zappa M, Vilgrain V, et al. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res 2011; 17:4504-4512
24. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011; 16(suppl 2):14-22
25. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011; 16(suppl 2):4-13
26. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002; 11:37-42 (Pubitemid 34053336)
27. Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 2008; 65: 123-131
28. Michaelson MD. ASCO 2006 highlights: targeted therapy for renal cell carcinoma. Cancer Treat Rev 2007; 33:381-390
29. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134 (Pubitemid 46089673)
30. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124 (Pubitemid 46089672)
31. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24 (Pubitemid 46630489)
32. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178:1883-1887 (Pubitemid 47538608)
33. Baccala A Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007; 14:1095-1097 (Pubitemid 350151265)
34. Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. AJR 2007; 189:360-370 (Pubitemid 47195921)
35. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR 2010; 194:157-165
36. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR 2010; 194:1470-1478
37. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012
38. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009; 9:587-595
39. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40:1825-1836
40. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007; 33:484-496 (Pubitemid 47333669)
41. Trinh VA. Current management of metastatic melanoma. Am J Health Syst Pharm 2008; 65(suppl 9):S3-S8
42. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106 (Pubitemid 46160986)
43. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723
44. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15:5591-5598
45. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-164
46. O'Day SJ, Maio M, Ciarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712-1717
47. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-7420
48. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105:3005-3010 (Pubitemid 351723658)
49. Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008; 5:557-561
50. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300
51. American Cancer Society. Cancer facts and figures 2010. American Cancer Society Website. www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-026238.pdf. Published 2010. Accessed December 19, 2011
52. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550 (Pubitemid 44917502)
53. Marom EM, Martinez CH, Truong MT, et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 2008; 3:351-357 (Pubitemid 351489474)
54. Crabb SJ, Patsios D, Sauerbrei E, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009; 27:404-410
55. Lee HY, Lee KS, Ahn MJ, et al. New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer 2011; 73:63-69
56. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-1703
57. Camidge DR. Progression-free survival (PFS) from a phase I study of crizotinib(PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29(suppl; abstr 2501)